378 results
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
8 May 24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
7:01am
of products as well as a decrease in our operational costs.
Research and Development (R&D) expenses, net in the first quarter of 2024 were $242 million … ,
Net revenues
Cost of sales
Gross profit
Research and development expenses
Selling and marketing expenses
General and administrative expenses
Intangible
8-K
EX-99.1
zxlverw cvypa4amq5
31 Jan 24
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
3vkbwp
8 Nov 23
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
7:01am
8-K
EX-99.1
rsl bdri8xpd32x
4 Oct 23
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
6:05am
8-K
EX-99.1
oe65cis
2 Aug 23
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
ylhrv
10 May 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
x5vkd a14d9jsu
3 Nov 22
Key financial highlights and outlook
7:00am
8-K
EX-99.1
47ojx r1tfsd
26 Jul 22
Key financial highlights and outlook
4:56pm
8-K
EX-99.1
8sgxsrywayw4 3y9
3 May 22
Results of Operations and Financial Condition
7:01am